NF2 and neoplasm: Knockdown of ANXA3, which is highly expressed in NF2−/− tumours irrespective of specific NF2 mutations (Fig. 4d, Supplementary Table S2 for clinical data), reduces proliferation as demonstrated by at least two proliferation assays (Fig. 6c and d).